Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EPDR1 promotes PD-L1 expression and tumor immune evasion by inhibiting TRIM21-dependent ubiquitylation of IkappaB kinase-β

16 Aug 2024

Abstract excerpt

Abstract While immune checkpoint blockade (ICB) has shown promise for clinical cancer therapy, its efficacy has only been observed in a limited subset of patients and the underlying mechanisms regulating innate and acquired resistance to ICB of tumor cells remain poorly understood. Here, we identified ependymin-related protein 1 (EPDR1) as an important tumor-intrinsic regulator of PD-L1 expression and tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Immune cells in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39152265
DOI: 10.1038/s44318-024-00201-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EPDR1 promotes PD-L1 expression and tumor immune evasion by inhibiting TRIM21-dependent ubiquitylation of IkappaB kinase-βPMID 39152265Read ↗

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune EvasionSemantic proximity Read ↗

Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer ImmunotherapySemantic proximity Read ↗

Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applicationsSemantic proximity Read ↗

m 6 A‐modified EHD1 controls PD‐L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinomaSemantic proximity Read ↗

The tumor suppressive role of KEAP1: Underlying mechanisms and therapeutic implications.Semantic proximity Read ↗

Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer ImmunotherapySemantic proximity Read ↗

RBM30 recruits DOT1L to activate STAT1 transcription and drive immune evasion in hepatocellular carcinomaSemantic proximity Read ↗

Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapySemantic proximity Read ↗

The Crossroads of Cancer Epigenetics and Immune Checkpoint TherapySemantic proximity Read ↗

The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in CancerSemantic proximity Read ↗

The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint BlockadeSemantic proximity Read ↗

Emerging concepts in PD-1 checkpoint biologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.